New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs

Japanese Journal of Neuropsychopharmacology

Volumn 23, Issue 3, 2003, Pages 111-119

  Asanuma, Masato ^a   Miyazaki, Ikuko ^a   Tsuji, Takeshi ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Inflammation; Neuroprotection; Nonsteroidal anti inflammatory drugs; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CELL NUCLEUS RECEPTOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTIPYRETIC ACTIVITY; DEGENERATIVE DISEASE; DRUG ACTIVITY; INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DEPRESSION, CHEMICAL; DOPAMINE; HUMANS; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PARKINSON DISEASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0037932475     PISSN: 13402544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Abramson, S. B., Leszczynska, P. J., Clancy, R. M., Philips, M. and Weissmann, G. (1994) Inhibition of neutrophil function by aspirin-like drugs (NSAIDS): Requirement for assembly of heterotrimeric G proteins in bilayer phospholipid. Biochem Pharmacol, 47: 563-572.
2. Aeberhard, E. E., Henderson, S. A., Arabolos, N. S., Griscavage, J. M., Castro, F. E., Barrett, C. T. and Ignarro, L. J. (1995) Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun, 208: 1053-1059.
3. Amin, A. R., Vyas, P., Attur, M., Leszczynska-Piziak, J., Patel, I. R., Weissmann, G. and Abramson, S. B. (1995) The mode of action of aspirin-like drugs: Effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA, 92: 7926-7930.
4. Anthony, J. C., Breitner, J. C., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C. and Stone, S. V. (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study. Neurology, 54: 2066-2071.
5. Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M. and Ogawa, N. (2001) Neuroprotective effects of nonsteroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem, 76: 1895-1904.
6. Asanuma, M., Miyazaki, I. and Ogawa, N. (2003) Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res, 5: 165-175.
7. Aubin, N., Curet, O., Deffois, A. and Carter, C. (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem, 71: 1635-1642.
8. Bauer, M. K., Lieb, K., Schulze-Osthoff, K., Berger, M., Gebicke-Haerter, P. J., Bauer, J. and Fiebich, B. L. (1997) Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem, 243: 726-731
9. 2 in the regulation of microglial functions. Eur J Neurosci, 12: 2215-2223.
10. Bisaglia, M., Venezia, V., Piccioli, P., Stanzione, S., Porcile, C., Russo, C., Mancini, F., Milanese, C. and Schettini, G. (2002) Acetaminophen protects hippocampal neurons and PC12 cultures from amyloid β-peptides induced oxidative stress and reduces NF-κB activation. Neurochem Int, 41: 43-54.
11. Blasko, I., Apochal, A., Boeck, G., Hartmann, T., Grubeck-Loebenstein, B. and Ransmayr, G. (2001) Ibuprofen decreases cytokine-induced amyloid β production in neuronal cells. Neurobiol Dis, 8: 1094-1101.
12. Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M. and Hirsch, E. C. (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem, 82: 615-624.
13. Breitner, J. C., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A., Roses, A. D., Pericak-Vance, M. A. and Saunders, A. M. (1995) Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging, 16: 523-530.
14. +: Protection by acetylsalicylic acid aspirin. Parkinsonism Relat Disord, 8: 407-411.
15. Casper, D., Yaparpalvi, U., Rempel, N. and Werner, P. (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett, 289: 201-204.
16. Castano, A., Herrera, A. J., Cano, J. and Machado, A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem, 70: 1584-1592.
17. Chen, L., Salafranca, M. N. and Mehta, J. L. (1997) Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol, 273: H1854-1859.
18. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B. and Landreth, G. E. (2000) Inflammatory mechanisms in Alzheimer's disease: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci, 20: 558-567.
19. Du, Z. Y. and Li, X. Y. (1999) Inhibitory effects of indomethacin on interteukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol, 21: 219-225.
20. Elbrecht, A., Chen, Y., Cullinan, C. A., Hayes, N., Leibowitz, M., Moller, D. E. and Berger, J. (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun, 224: 431-437.
21. Farivar, R. S., Chobanian, A. V. and Brecher, P. (1996) Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Circ Res, 78: 759-768.
22. Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K. and Oertel, W. H. (1999) Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol, 360: 256-261.
23. Frantz, B. and O'Neill, E. A. (1995) The effect of sodium salicylate and aspirin on NF-κB. Science, 270: 2017-2019.
24. Gao, H. M., Jiang, J., Wilson, B., Zhang, W., Hong, J. S. and Liu, B. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem, 81: 1285-1297.
25. Goto, M., Kimura, T., Hagio, S., Ueda, K., Kitajima, S., Tokunaga, H. and Sato, E. (1995) Neuropathological analysis of dementia in a Japanese leprosarium. Dementia, 6: 157-161.
26. Gottschall, P. E. (1996) β-Amyloid induction of gelatinase B secretion in cultured microglia: Inhibition by dexamethasone and indomethacin. Neuroreport, 7: 3077-3080.
27. Grilli, M., Pizzi, M., Memo, M. and Spano, P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science, 274: 1383-1385.
28. Hastings, T. G. (1995) Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem, 64: 919-924.
29. Hauss-Wegrzyniak, B., Vraniak, P. and Wenk, G. L. (1999) The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging, 20: 305-313.
30. Heneka, M. T., Feinstein, D. L., Galea, E., Gleichmann, M., Wullner, U. and Klockgether, T. (1999) Peroxisome proliferator-activated receptor γ agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol, 100: 156-168.
31. Heneka, M. T., Klockgether, T. and Feinstein, D. L. (2000) Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci, 20: 6862-6867.
32. Hoozemans, J. J., Rozemuller, A. J., Janssen, I., De Groot, C. J., Veerhuis, R. and Eikelenboom, P. (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl), 101: 2-8.
33. Humes, J. L., Winter, C. A., Sadowski, S. J. and Kuehl Jr, F. A. (1981) Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal antiinflammatory agents. Proc Natl Acad Sci USA, 78: 2053-2056.
34. Hunot, S., Hartmann, A. and Hirsch, E. C. (2001) The inflammatory response in the Parkinson brain. Clin Neurosci Res, 1: 434-443.
35. Inoue, H., Tanabe, T. and Umesono, K. (2000) Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem, 275: 28028-28032.
36. in't Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. and Stricker, B. H. (1998) NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging, 19: 607-611.
37. in't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. and Stricker, B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med, 345: 1515-1521.
38. Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D. and Gordon, M. N. (2002) Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci, 22: 2246-2254.
39. Jiang, C., Ting, A. T. and Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature, 391: 82-86.
40. Katsuyama, K., Shichiri, M., Kato, H., Imai, T., Marumo, F. and Hirata, Y. (1999) Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. Endocrinology, 140: 2183-2190.
41. Kepka-Lenhart, D., Chen, L. C. and Morris, S. M. J. (1996) Novel actions of aspirin and sodium salicylate: Discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. J Leukoc Biol, 59: 840-846.
42. Kielian, T. and Drew, P. D. (2003) Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation. J Neurosci Res, 71: 315-325.
43. Kim, H., Lee, E., Shin, T., Chung, C. and An, N. (1998). Inhibition of the induction of the inducible nitric oxide synthase in murine brain microglial cells by sodium salicylate. Immunology, 95: 389-394.
44. Kitamura, Y., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P. J. and Taniguchi, T. (1999a) Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett, 262: 129-132.
45. Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P. J. and Taniguchi, T. (1999b) Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-g in Alzheimer's disease brains. Biochem Biophys Res Commun, 254: 582-586.
46. Knott, C., Stern, G. and Wilkin, G. P. (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci. 16: 724-739.
47. Kopp, E. and Ghosh, S. (1994) Inhibition of NF-κB by sodium salicylate and aspirin. Science, 265: 956-959.
48. Kwon, G., Hill, J. R., Corbett, J. A. and McDaniel, M. L. (1997) Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol, 52: 398-405.
49. Landreth, G. E. and Heneka, M. T. (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease. Neurobiol Aging, 22: 937-944.
50. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. and Kliewer, S. A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 272: 3406-3410.
51. Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A. and Cole, G. M. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci, 20: 5709-5714.
52. Lipton, S. A. (1997) Janus faces of NF-κB: Neurodestruction versus neuroprotection. Nat Med, 3: 20-22.
53. Mackenzie, I. R. and Munoz, D. G. (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology, 50: 986-990.
54. Mattammal, M. B., Strong, R., Lakshmi, V. M., Chung, H. D. and Stephenson, A. H. (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem, 64: 1645-1654.
55. McGeer, P. L. (2000) Cyclo-oxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease. Drugs Aging, 17: 1-11.
56. McGeer, P. L. and McGeer, E. G. (1995) The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev, 21: 195-218.
57. McGeer, P. L. and Rogers, J. (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 42: 447-449.
58. McGeer, P. L., Itagaki, S., Boyes, B. E. and McGeer, E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38: 1285-1291.
59. McGeer, P. L., Schulzer, M. and McGeer, E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47: 425-432.
60. Meade, E. A., Smith, W. L. and DeWitt, D. L. (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 268: 6610-6614.
61. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12: 2005-2015.
62. Mirza, B., Hadberg, H., Thomsen, P. and Moos, T. (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience, 95: 435-433.
63. Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J. and Vane, J. R. (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA, 90: 11693-11697.
64. Mohanakumar, K. P., Muralikrishnan, D. and Thomas, B. (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res, 864: 281-290.
65. Murphy, S., Simmons, M. L., Agullo, L., Garcia, A., Feinstein, D. L., Galea, E., Reis, D. J., Minc, G. D. and Schwartz, J. P. (1993) Synthesis of nitric oxide in CNS glial cells. Trends Neurosci, 16: 323-328.
66. Nagatsu, T., Mogi, M., Ichinose, H. and Togari, A. (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl: 277-290.
67. Netland, E. E., Newton, J. L., Majocha, R. E. and Tate, B. A. (1998) Indomethacin reverses the microglial response to amyloid β-protein. Neurobiol Aging, 19: 201-204.
68. O'Neill, L. A. J. and Kaltschmidt, C. (1997) NF-κB: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci, 20: 252-258.
69. Pasinetti, G. M. and Aisen, P. S. (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 87: 319-324
70. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 391: 79-82.
71. Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., Ward, P. and Lieberburg, I. (1992) Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA, 89: 10016-10020.
72. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P. and Kogan, F. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43: 1609-1611.
73. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M. and Santoro, M. G. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature, 403: 103-108.
74. Sakitani, K., Kitade, H., Inoue, K., Kamiyama, Y., Nishizawa, M., Okumura, T. and Ito, S. (1997) The anti-inflammatory drug sodium salicylate inhibits nitric oxide formation induced by interleukin-1β at a translational step, but not at a transcriptional step, in hepatocytes. Hepatology, 25: 416-420.
75. Salvemini, D., Misko, T. P., Masferrer, J. L., Seibert, K., Currie, M. G. and Needleman, P. (1993) Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA, 90: 7240-7244.
76. Sanchez de Miguel, L., de Frutos, T., Gonzalez-Fernandez, F., del Pozo, V., Lahoz, C., Jimenez, A., Rico, L., Garcia, R., Aceituno, E., Millas, I., Gomez, J., Farre, J., Casado, S. and Lopez, F. A. (1999) Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-α release by cultured smooth muscle cells. Eur J Clin Invest, 29: 93-99.
77. Scharf, S., Mander, A., Ugoni, A., Vajda, F. and Christophidis, N. (1999) A double-blind, placebo-controlled trial of diclofenac/ misoprostol in Alzheimer's disease. Neurology, 53: 197-201.
78. Simpson, C. S. and Morris, B. J. (1999) Activation of nuclear factor κB by nitric oxide in rat striatal neurones: Differential inhibition of the p50 and p65 subunits by dexamethasone. J Neurochem, 73: 353-361.
79. Stern, E. L., Quan, N., Proescholdt, M. G. and Herkenham, M. (2000) Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. J Neuroimmunol, 109: 245-260.
80. Stewart, W. F., Kawas, C., Corrada, M. and Metter, E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48: 626-632.
81. Teismann, P. and Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Syn. apse, 39: 167-174.
82. Tocco, G., Freire-Moar, J., Schreiber, S. S., Sakhi, S. H., Aisen, P. S. and Pasinetti, G. M. (1997) Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: Implications for Alzheimer's disease. Exp Neurol, 144: 339-349.
83. Vane, J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 231: 232-235.
84. Walker, D. G. and McGeer, P. L. (1992) Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res, 14: 109-116.
85. Weber, C., Erl, W., Pietsch, A. and Weber, P. C. (1995) Aspirin inhibits nuclear factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation, 91: 1914-1917.
86. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E. and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature, 414: 212-216.
87. Yang, X. Y., Wang, L. H., Chen, T., Hodge, D. R., Resau, J. H., DaSilva, L. and Farrar, W. L. (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J Biol Chem, 275: 4541-4544.